A phase i study of sirolimus and bevacizumab in patients with advanced malignancies

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1484-1489

  Cohen, E E W ^a,b   Sharma, M R ^a   Janisch, L ^a   Llobrera, M ^a   House, L ^a   Wu, K ^a   Ramirez, J ^a   Fleming, G F ^a   Stadler, W M ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 2115 ^*  (United States)

Author keywords

Bevacizumab; Phase I; Sirolimus

Indexed keywords

BEVACIZUMAB; RAPAMYCIN;

ADENOID CYSTIC CARCINOMA; ADRENAL CORTEX CARCINOMA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ANOREXIA; APPENDIX CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRY SKIN; DYSPNEA; ENDOMETRIUM CANCER; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOXEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LUNG CARCINOID; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RECTUM CANCER; SARCOMA; SIDE EFFECT; SMALL BLUE ROUND CELL TUMOR; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; TUMOR; UROGENITAL TRACT TUMOR; UTERINE CERVIX CANCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 79958775065     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.017     Document Type: Article

References (27)

1. K.L. Napoli, and P.J. Taylor From beach to bedside: history of the development of sirolimus Ther Drug Monit 23 5 2001 559 586 Review (Pubitemid 32912281)
2. M. Liu, A. Howes, and J. Lesperance Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer Cancer Res 65 12 2005 5325 5336 (Pubitemid 40827345)
3. R. Namba, L.J. Young, and C.K. Abbey Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ Clin Cancer Res 12 8 2006 2613 2621
4. A. Jimeno, M.A. Rudek, and P. Kulesza Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors J Clin Oncol 26 25 2008 4172 4179
5. M.J. Ratain, K.L. Napoli, and K. Knightley-Moshier A phase Ib study of oral rapamycin (sirolimus) in patients with advanced malignancies J Clin Oncol 25 2007 140s (suppl; abstr 3510)
6. A.J. Wagner, I. Malinowska-Kolodziej, and J.A. Morgan Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors J Clin Oncol 28 5 2010 835 840
7. C.M. Hartford, and M.J. Ratain Rapamycin: something old, something new, sometimes borrowed and now renewed Clin Pharmacol Ther 82 4 2007 381 388 (Review) (Pubitemid 47414349)
8. E.E. Cohen MTOR: the mammalian target of replication J Clin Oncol 26 3 2008 348 349 (Pubitemid 351171681)
9. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2007 2271 2281 (Pubitemid 46849157)
10. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
11. J.D. Hainsworth, D.R. Spigel, and H.A. Burris 3rd Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 13 2010 2131 2136
12. J.J. Zimmerman, G.M. Ferron, and H.K. Lim The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin) J Clin Pharmacol 39 11 1999 1155 1161 (Pubitemid 30644018)
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
14. J.J. Zimmerman, and B.D. Kahan Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration J Clin Pharmacol 37 5 1997 405 415 (Pubitemid 27215068)
15. B.J. Escudier, S. Negrier, and G. Gravis Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma? Results of the randomized TORAVA phase II trial J Clin Oncol 28 2010 15s (suppl; abstr 4516)
16. I. Altomare, K.B. Russell, and H.E. Uronis Phase II trial of bevacizumab plus everolimus for refractory metastatic colorectal cancer J Clin Oncol 28 2010 15s 2010 (abstr 3535)
17. [cited November 22, 2010] http://www.clinicaltrials.gov/ct2/show/ NCT00467194?term=bevacizumab+sirolimus&rank=2.
18. [cited November 22, 2010] http://www.clinicaltrials.gov/ct2/show/ NCT01083368?term=bevacizumab+sirolimus&rank=3.
19. [cited November 22, 2010] http://www.clinicaltrials.gov/ct2/show/ NCT00723255?term=bevacizumab+sirolimus&rank=17.
20. [cited November 22, 2010] http://www.clinicaltrials.gov/ct2/show/ NCT00800917?term=bevacizumab+sirolimus&rank=19.
21. [cited November 22, 2010]. http://www.clinicaltrials.gov/ct2/show/ NCT01031381?term=bevacizumab+sirolimus&rank=5.
22. [cited December 7, 2010] http://www.clinicaltrials.gov/ct2/show/ NCT01198158?term=everolimus+bevacizumab+CALGB&rank=2.
23. N.J. Montvale Drug Topics Red Book 2010 Thomson Healthcare
24. K. Mahalati, and B.D. Kahan Clinical pharmacokinetics of sirolimus Clin Pharmacokinet 40 8 2001 573 585 (Review) (Pubitemid 32758580)
25. T. Gangadhar, E.E. Cohen, and L. Janisch A drug interaction study of sorafenib (S), rapamycin (R) in patients with advanced malignancies J Clin Oncol 26 2008 15s (suppl; abstr 2545)
26. S.B. Stenton, N. Partovi, and M.H. Ensom Sirolimus: the evidence for clinical pharmacokinetic monitoring Clin Pharmacokinet 44 8 2005 769 786 (Review) (Pubitemid 41126927)
27. J.P. Boni, B. Hug, C. Leister, and D. Sonnichsen Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations Semin Oncol 36 Suppl 3 2009 S18 S25 (Review)